retatrutide clinical trial phase Eli Lilly's 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Today, we shared new data

All dosage information below comes from published clinical trial data

Eli Lilly spent years optimizing the triple agonist design through peptide research and clinical studies

Jan 20, 2026 9 min read READ MORE Fitness GLP-1 and Strength Training: Avoiding a Common Pitfall Losing weight on a GLP-1 medication

For most GLP-1 users, standing head rushes are the most common form of dizziness and dissipate after a few moments

The foundation's annual youth survey found that more than half of all young people aged 12-18 reported being dissatisfied with their bodies in 2024

Probiotic GLP-1 supplements as finished products have not been studied in published randomized controlled trials comparable to pharmaceutical research